Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 37 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy				Phase III				12002 NCT00306150
	Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer				Phase III				EFC6668 XRP9881, NCT00625664
	E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction				Phase II, Phase I				CCC-PHII-75 7435, NCI-7435, NCT00365157
	Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant				Phase II				MDA-ID-030111 NCT00082706
	Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer				Phase II				HOG GU04-75 NCT00234494
	Randomized Phase II Study for Patients With Previously Treated Advanced Urothelial Cancer				Phase II				FER-GU-004 NCT00350025
	Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium				Phase II				MSKCC-06081 NCT00397488
	Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma				Phase II				UMCC 2005.145 NCT00393796
	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor				Phase II				CINJ-3330 NCT00161187
	Pazopanib in Treating Patients With Metastatic Urothelial Cancer				Phase II				MCCRC-MC0553 7661, MC0553, NCT00471536


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute